VolitionRx to Acquire BioCheck for $10M
Ticker: VNRX · Form: 8-K · Filed: Sep 16, 2024 · CIK: 93314
Sentiment: neutral
Topics: acquisition, biotech, diagnostics
TL;DR
VolitionRx buying BioCheck for $10M, closing Q4 2024.
AI Summary
VolitionRx Limited announced on September 16, 2024, that it has entered into a definitive agreement to acquire all of the outstanding equity interests of BioCheck, Inc. for an aggregate purchase price of $10.0 million. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions.
Why It Matters
This acquisition could expand VolitionRx's diagnostic capabilities and market reach, potentially leading to increased revenue and market share in the life sciences sector.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges, potential overpayment, and failure to achieve expected synergies, which could impact VolitionRx's financial performance.
Key Numbers
- $10.0M — Acquisition Price (Total consideration for BioCheck, Inc.)
Key Players & Entities
- VolitionRx Limited (company) — Acquiring company
- BioCheck, Inc. (company) — Acquired company
- $10.0 million (dollar_amount) — Aggregate purchase price
- September 16, 2024 (date) — Announcement date
- fourth quarter of 2024 (date) — Expected closing period
FAQ
What is the primary strategic rationale behind VolitionRx's acquisition of BioCheck, Inc.?
The filing does not explicitly detail the strategic rationale beyond the acquisition itself, but it is implied to be for expanding diagnostic capabilities and market reach.
What is the expected closing date for the acquisition of BioCheck, Inc.?
The acquisition is expected to close in the fourth quarter of 2024.
What is the total purchase price for BioCheck, Inc.?
The aggregate purchase price for all outstanding equity interests of BioCheck, Inc. is $10.0 million.
Are there any specific closing conditions mentioned for the acquisition?
Yes, the transaction is subject to customary closing conditions.
What is the legal jurisdiction of VolitionRx Limited?
VolitionRx Limited is incorporated in Delaware.
Filing Stats: 569 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2024-09-16 16:19:29
Key Financial Figures
- $0.001 — ch Registered Common Stock, par value $0.001 per share VNRX NYSE American, LLC
Filing Documents
- vnrx_8k.htm (8-K) — 27KB
- vnrx_ex991.htm (EX-99.1) — 2KB
- vnrx_ex991img1.jpg (GRAPHIC) — 229KB
- vnrx_ex991img2.jpg (GRAPHIC) — 173KB
- 0001477932-24-005745.txt ( ) — 705KB
- vnrx-20240916.xsd (EX-101.SCH) — 6KB
- vnrx-20240916_lab.xml (EX-101.LAB) — 14KB
- vnrx-20240916_cal.xml (EX-101.CAL) — 1KB
- vnrx-20240916_pre.xml (EX-101.PRE) — 9KB
- vnrx-20240916_def.xml (EX-101.DEF) — 2KB
- vnrx_8k_htm.xml (XML) — 4KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. From September 16, 2024, VolitionRx Limited (the " Company ") is making available to third parties, including through its licensing adviser, PharmaVentures Limited, a document providing a brief introduction to certain components of the Company's oncology portfolio available to out license. A copy of the document is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated in this Item 7.01 in its entirety. The information contained in, or incorporated into, this Item 7.01 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference to such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Brief Overview of Certain Oncology Assets, issued September 16, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VOLITIONRX LIMITED Date: September 16, 2024 By: /s/ Cameron Reynolds Cameron Reynolds Chief Executive Officer & President 3 EXHIBIT INDEX Exhibit Number Description 99.1 Brief Overview of Certain Oncology Assets, issued September 16, 2024. 4